N/A Completed N=105 Single-blind Diagnostic

Pancreatic Juice Diagnosis From Duodenum

pancreatic adenocarcinoma

Source: ClinicalTrials.gov NCT01699698 ↗

Enrolled (actual)

105

Serious AEs

0.0%

Results posted

Sep 2015

Primary outcomePrimary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001

Summary

Purpose of this study is to understand the clinical feasibility of duodenal juice diagnosis to screen UICC stage II pancreatic ductal adenocarcinoma patients.

Outcome Measures

Outcome	Result	p-value
PRIMARY The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort	99097; 34095	<0.001 sig
SECONDARY The Sensitivity and Specificity to Detect UICC Stage II Pancreatic Ductal Adenocarcinoma Among All Participants.	31; 17	—

Eligibility Criteria

Inclusion Criteria

Common inclusion criterion
Age is 18 years or older.
Informed consent was obtained.
Inclusion criterion for normal cohort
An upper GI endoscopy is scheduled to check upper abdominal symptoms.
No findings of pancreatic disorder as documented by CT or MRI or EUS
Inclusion criterion for PC suspicious cohort
A EUS or ERCP is scheduled to suspected pancreatic disorder.

Exclusion Criteria

Common exclusion criterion
Severe cardiac disease
Severe respiratory disease
Bleeding disorders
Pregnancy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01699698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.